“Atlas lodged its Target’s Statement in relation to the Hancock Offer with ASX on 16 July 2018. The Target’s Statement includes a report from an independent expert, which concludes that the Hancock Offer is fair and reasonable to Atlas shareholders.”
DYOR:
IE report is based on valuing AGO as only a going-concern, and does not include all the synergies that HPPL/FMG will bring to the table.
- Forums
- ASX - By Stock
- AGO
- Ann: Further conditional increase to Hancock Offer
Ann: Further conditional increase to Hancock Offer, page-11
-
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AGO (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online